<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408367</article-id><article-id pub-id-type="pmc">PMC12101690</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0324788</article-id><article-id pub-id-type="publisher-id">PONE-D-24-57829</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Tropical Diseases</subject><subj-group><subject>Neglected Tropical Diseases</subject><subj-group><subject>Leishmaniasis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Parasitic Diseases</subject><subj-group><subject>Protozoan Infections</subject><subj-group><subject>Leishmaniasis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Zoonoses</subject><subj-group><subject>Leishmaniasis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Socioeconomic Aspects of Health</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Socioeconomic Aspects of Health</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Quality of Life</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Lesions</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>South America</subject><subj-group><subject>Brazil</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Psychological and Psychosocial Issues</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Skin Diseases</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Dermatology</subject><subj-group><subject>Skin Diseases</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Pain</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Health-related quality of life in Brazilian patients with cutaneous leishmaniasis using EQ-5D</article-title><alt-title alt-title-type="running-head">Health-related quality of life in Brazilian patients with cutaneous leishmaniasis</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0875-3600</contrib-id><name><surname>Carvalho</surname><given-names>Jana&#x000ed;na de Pina</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1087-9819</contrib-id><name><surname>Silva</surname><given-names>Sarah Nascimento</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>de Assis</surname><given-names>T&#x000e1;lia Santana Machado</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Galv&#x000e3;o</surname><given-names>Endi Lanza</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>Mayra Soares</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6821-1598</contrib-id><name><surname>Andrade</surname><given-names>M&#x000f4;nica Viegas</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>de Souza Noronha</surname><given-names>Kenya Val&#x000e9;ria Micaela</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cota</surname><given-names>Gl&#x000e1;ucia</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff001"><label>1</label>
<addr-line>Pesquisa Cl&#x000ed;nica e Pol&#x000ed;ticas P&#x000fa;blicas em Doen&#x000e7;as Infecciosas e Parasit&#x000e1;rias, N&#x000fa;cleo de Avalia&#x000e7;&#x000e3;o de Tecinologias em Sa&#x000fa;de, Instituto Ren&#x000e9; Rachou, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Centro Federal de Educa&#x000e7;&#x000e3;o Tecnol&#x000f3;gica de Minas Gerais, Campus Contagem, Contagem, Minas Gerais, Brazil</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Programa de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Reabilita&#x000e7;&#x000e3;o e Desempenho Funcional, Departamento de Fisioterapia, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Centro de desenvolvimento e Planejamento Regional, Faculdade de Ci&#x000ea;ncias Econ&#x000f4;micas da Universidade Federal de Minas Gerais, Minas Gerais, Brazil</addr-line></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Belo</surname><given-names>Vin&#x000ed;cius Silva</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib><aff id="edit1">
<addr-line>UFSJ: Universidade Federal de Sao Joao del-Rei, BRAZIL</addr-line>
</aff></contrib-group><author-notes><fn fn-type="COI-statement" id="coi002"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>sarah.nascimento@fiocruz.br</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0324788</elocation-id><history><date date-type="received"><day>30</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Carvalho et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Carvalho et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0324788.pdf">
</self-uri><abstract><p>Cutaneous leishmaniasis (CL) is a neglected infectious disease with a global distribution and a known health-related quality of life (HRQoL) impact. However, no utility-based HRQoL assessments for CL patients are available. The aim of this study was to quantitatively assess the health-related quality of life among patients with CL attending a Brazilian reference center. A retrospective interview-based longitudinal study was conducted using the EQ-5D-3L/VAS to assess the current health status during active disease, and retrospectively before the onset of disease symptoms. In addition, socioeconomic data were collected via a standardized questionnaire, and sociodemographic and clinical data were collected directly from medical records. A total of 143 patients with a mean age of 52 (&#x000b1;17) years were included, 73% of whom were men. The mean utility score before the onset of CL symptoms was 0.858. Comparison of responses related to health status before and after disease onset revealed significant losses (p&#x02009;&#x0003c;&#x02009;0.05) in all dimensions of the EQ-5D, especially those related to pain, malaise (50%) and usual activities (27%). CL also affected the median Visual Analogue Scale (VAS) score and utility score, which were 87 and 70 and 0.858 and 0.716, respectively. These results confirm the substantial negative impact of CL on all assessed dimensions of life, highlighting its role in perpetuating the cycle of suffering and poverty associated with neglected tropical diseases.</p></abstract><funding-group><award-group id="award001"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003593</institution-id><institution>Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico</institution></institution-wrap>
</funding-source><award-id>302069/2022-4</award-id><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7824-3542</contrib-id>
<name><surname>Cota</surname><given-names>Gl&#x000e1;ucia</given-names></name>
</principal-award-recipient></award-group><funding-statement>Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico - CNPq (GC grant: 302069/2022-4)</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>A/PROS @ ACCCEPT Please follow up for data available upon acceptance: The dataset will be published after approval of the manuscript. Previous information is available in the Mendeley repository (not published). Silva, Sarah (2025), &#x0201c;Health-related quality of life in Brazilian patients with cutaneous leishmaniasis using EQ-5D_dataset&#x0201d;, Mendeley Data, V1, doi: 10.17632/mh7zrrcxcy.1"</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>A/PROS @ ACCCEPT Please follow up for data available upon acceptance: The dataset will be published after approval of the manuscript. Previous information is available in the Mendeley repository (not published). Silva, Sarah (2025), &#x0201c;Health-related quality of life in Brazilian patients with cutaneous leishmaniasis using EQ-5D_dataset&#x0201d;, Mendeley Data, V1, doi: 10.17632/mh7zrrcxcy.1"</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Cutaneous leishmaniasis (CL) is a neglected infectious parasitic disease that is widely distributed worldwide [<xref rid="pone.0324788.ref001" ref-type="bibr">1</xref>]. In the Americas, 37,890 CL and mucosal leishmaniasis (ML) cases were reported in 2022, with Brazil accounting for 34% of these cases [<xref rid="pone.0324788.ref002" ref-type="bibr">2</xref>]. The lesions caused by CL on the skin or mucosa can result in disfiguring and stigmatizing scars. In more severe instances, these lesions may lead to functional impairments in the respiratory and digestive tracts, significantly affecting the quality of life of those impacted [<xref rid="pone.0324788.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0324788.ref004" ref-type="bibr">4</xref>].</p><p>The concept of quality of life (QoL) encompasses both subjectivity and multidimensionality, incorporating various aspects, such as physical, psychological, and social dimensions [<xref rid="pone.0324788.ref005" ref-type="bibr">5</xref>]. In terms of an individual&#x02019;s perception of their emotional state, functionality, and social interactions, the assessment of QoL has become a significant health outcome to be considered alongside traditional metrics of efficacy, safety, and mortality (duration of life). The estimation of how diseases and health interventions affect QoL is understood as health-related quality of life (HRQoL) [<xref rid="pone.0324788.ref006" ref-type="bibr">6</xref>], a term widely used in evaluating and comparing chronic and infectious diseases such as diabetes and HIV infection [<xref rid="pone.0324788.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0324788.ref008" ref-type="bibr">8</xref>]. In these contexts, beyond the duration of life, the impact on psychosocial dimensions and the overall functionality of the patient are the most relevant aspects to measure [<xref rid="pone.0324788.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0324788.ref009" ref-type="bibr">9</xref>].</p><p>Studies conducted in endemic regions have explored the impact of CL on patients&#x02019; QoL, using various assessment tools [<xref rid="pone.0324788.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0324788.ref010" ref-type="bibr">10</xref>&#x02013;<xref rid="pone.0324788.ref022" ref-type="bibr">22</xref>]. Instruments developed for skin diseases, such as the Dermatology Life Quality Index (DLQI) [<xref rid="pone.0324788.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0324788.ref017" ref-type="bibr">17</xref>] and the Skindex-29 [<xref rid="pone.0324788.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0324788.ref022" ref-type="bibr">22</xref>], are commonly used, as are tools that address psychiatric aspects [<xref rid="pone.0324788.ref020" ref-type="bibr">20</xref>] or even instruments specific to CL, such as the Cutaneous Leishmaniasis Impact Questionnaire (CLIQ) [<xref rid="pone.0324788.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0324788.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0324788.ref015" ref-type="bibr">15</xref>]. In addition, generic instruments such the World Health Organization Quality of Life Brief Version (WHOQOL-bref) [<xref rid="pone.0324788.ref003" ref-type="bibr">3</xref>] and the European Quality of Life 5 Dimensions 3 Levels (EQ-5D-3L) have been used to assess HRQoL in these patients [<xref rid="pone.0324788.ref022" ref-type="bibr">22</xref>].</p><p>One of the main advantages of the standardized use of generic instruments is the ability to measure health outcomes, which allows comparisons between different interventions and technologies. While disease-specific instruments, such as the DLQI, provide detailed insights into dermatological and psychosocial aspects, they do not generate utility scores necessary for economic evaluation. This, in turn, enhances the decision-making process for their incorporation into health systems. The EQ-5D-3L specifically measures HRQoL via a utility indicator that reflects social preferences for health states. One of the key outcomes in economic evaluations is Quality-Adjusted Life Years (QALYs), which consider both the dimensions of QoL and survival time in a single measure. In this regard, the aim of this study was to measure for the first time the HRQoL of patients affected by CL attending a Brazilian reference center, using the EQ-5D-3L. This instrument, developed by the EuroQol [<xref rid="pone.0324788.ref023" ref-type="bibr">23</xref>] group, is currently the most widely used in the world, mainly due to its simplicity and comprehensiveness, and has already been validated in Brazil [<xref rid="pone.0324788.ref024" ref-type="bibr">24</xref>,<xref rid="pone.0324788.ref025" ref-type="bibr">25</xref>].</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Study design and data collection</title><p>This retrospective, longitudinal, interview-based study sought to include patients with CL diagnosis evaluated at a Reference Center for Leishmaniasis in Minas Gerais (MG), Brazil, using a convenience sample of cases consecutively enrolled between October 1<sup>st</sup>, 2020 and April 30<sup>th</sup>, 2023, without predefined exclusion criteria. No formal sample size calculation was conducted prior to data collection. Instead, the sample size was determined based on feasibility and the availability of patients during the study period, with the objective of including as many eligible participants as possible. The selection criteria were an age of 12 years or older and a diagnosis of CL. Patients were consecutively recruited based on an opportunity window for an individual interview before the start of specific treatment using the EQ-5D-3&#x02009;L instrument (Portuguese version for Brazil, v1.0, with adaptations for each moment of the interview). Two researchers and two trained students conducted the interviews after obtaining written consent from the participants. Written informed consent was obtained from the parents or legal guardian of participants under 18 years old using Informed Consent Form (ICF), and Assent Form (AF) was obtained from the children prior to participation. During the initial contact with the patient, which occurred shortly after diagnosis (active CL), participants reported their current health status (<xref rid="pone.0324788.s001" ref-type="supplementary-material">S1 Appendix</xref>) and were asked to reflect on their condition over the previous 30 days. Given the difficulties of interviewing the entire population at risk, and in order to assess the health status of the same patients before CL onset, they were asked to retrospectively report their health condition just prior to the appearance of disease symptoms (<xref rid="pone.0324788.s002" ref-type="supplementary-material">S2 Appendix</xref>), immediately after the first interview, without specifying a timeframe. At the same time, the participants also completed a questionnaire on socioeconomic conditions (<xref rid="pone.0324788.s003" ref-type="supplementary-material">S3 Appendix</xref>). Sociodemographic and clinical information were collected directly from medical records.</p></sec><sec id="sec004"><title>Data collection instruments</title><p>The EQ-5D-3L was used after approval from the EuroQol Group (ID 33742). The first part of the questionnaire assesses health status across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with three levels of intensity (no problems, moderate problems, and extreme problems). The combination of the five dimensions and three levels of intensity results in 243 distinct health states. These range from having no problems in any dimension (the best health state), represented by 11111, to experiencing extreme problems across all dimensions, represented by 33333. Each health state can be assigned a utility measure that reflects societal preferences for these conditions. Additionally, in the second part of the interview, participants assessed their health status via a visual analog scale (VAS), where values ranged from the worst imaginable (0) to the best (100) health state [<xref rid="pone.0324788.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0324788.ref026" ref-type="bibr">26</xref>].</p><p>The socioeconomic status of the respondents was categorized according to the Brazil Economic Classification Criteria established by the Brazilian Association of Research Companies (<italic toggle="yes">Associa&#x000e7;&#x000e3;o Brasileira de Empresas de Pesquisa</italic>&#x02014;ABEP), 2019, on the basis of average family income, as follows: A (R$ 25,554.33), B1 (R$ 11,279.14), B2 (R$ 5,641.64), C1 (R$ 3,085.48), C2 (R$ 1,748.59), and DE (R$ 719.81) [<xref rid="pone.0324788.ref027" ref-type="bibr">27</xref>].</p><p>Sociodemographic information (sex, age, education level, municipality of residence) and clinical data (clinical form of leishmaniasis, location of the lesion, type of case&#x02014;new or recurrence, presence of comorbidities, alcohol use, drug use, previous treatments) were extracted from medical records via a structured form. The age groups were categorized based on epidemiological relevance and sample distribution to ensure a balanced representation of participants across different life stages, allowing for meaningful comparisons within the study population. This study was approved by the Ren&#x000e9; Rachou Institute/Fiocruz Minas&#x02019;s ethics committee under number CAAE: 28929220.0.0000.5091 (approval date: March 16, 2020).</p></sec><sec id="sec005"><title>Data analysis</title><p>Each patient&#x02019;s health status was assessed via the EQ-5D-3L instrument, which was transformed into a utility metric. Utility values representing social preferences for health states in the Brazilian population, as estimated by Santos et al. (2016) [<xref rid="pone.0324788.ref024" ref-type="bibr">24</xref>], were considered (available at &#x0003c;<ext-link xlink:href="https://atsinc.com.br/eq-5d-menu/" ext-link-type="uri">https://atsinc.com.br/eq-5d-menu/</ext-link>&#x0003e;) [<xref rid="pone.0324788.ref028" ref-type="bibr">28</xref>]. Differences in average utility between the various subgroups, based on the patients&#x02019; clinical and sociodemographic characteristics, both before CL and with active disease, were evaluated via the nonparametric Wilcoxon test. Additionally, differences in utility scores across multiple categories of clinical and sociodemographic variables were assessed using the Mann&#x02013;Whitney U test (for two groups) or the Kruskal&#x02013;Wallis test (for three or more groups), depending on the number of categories within each variable.</p><p>The losses in HRQoL were estimated by comparing the proportion of responses before CL onset with those during its active phase. This comparison was made across three levels of problem intensity&#x02014;no problems, some problems, and extreme problems&#x02014;in each of the five assessed dimensions. Differences between groups were analyzed via the Stuart&#x02012;Maxwell test for marginal homogeneity of categorical variables and the Wilcoxon test for continuous variables. A significant level of 5% was established for all tests; all analyses were performed in the Statistical Package for the Social Sciences - SPSS software (v. 23).</p></sec></sec><sec sec-type="results" id="sec006"><title>Results</title><p>A total of 152 patients diagnosed with CL were invited to participate, representing 47% (152/321) of the total eligible population during the study period. Of these, 143 individuals (93% of those invited) agreed to participate, with an average age of 52 years (&#x000b1;17) among the included patients. <bold><xref rid="pone.0324788.t001" ref-type="table">Table 1</xref></bold> presents the general characteristics of the sample.</p><table-wrap position="float" id="pone.0324788.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0324788.t001</object-id><label>Table 1</label><caption><title>Sociodemographic, economic, and clinical characteristics of patients with active cutaneous leishmaniasis treated at a Brazilian referral center between 2020 and 2023 and their impact on health-related quality of life (N&#x02009;=&#x02009;143).</title></caption><alternatives><graphic xlink:href="pone.0324788.t001" id="pone.0324788.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" rowspan="1" colspan="1">N</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">Mean utility (Before CL)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p-value</italic>
</th><th align="left" rowspan="1" colspan="1">Mean utility (Active CL)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p-value</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" rowspan="1" colspan="1">105</td><td align="left" rowspan="1" colspan="1">73%</td><td align="left" rowspan="1" colspan="1">0.877</td><td align="left" rowspan="1" colspan="1">0.084</td><td align="left" rowspan="1" colspan="1">0.749</td><td align="left" rowspan="1" colspan="1">0.001*</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">27%</td><td align="left" rowspan="1" colspan="1">0.805</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.626</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Under 25</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">8%</td><td align="left" rowspan="1" colspan="1">0.852</td><td align="left" rowspan="1" colspan="1">0.492</td><td align="left" rowspan="1" colspan="1">0.718</td><td align="left" rowspan="1" colspan="1">0.925</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;25-49</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">29%</td><td align="left" rowspan="1" colspan="1">0.886</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.728</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;50-74</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">54%</td><td align="left" rowspan="1" colspan="1">0.849</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.720</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Over 74</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">9%</td><td align="left" rowspan="1" colspan="1">0.824</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.653</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Region</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Minas Gerais Countryside</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">41%</td><td align="left" rowspan="1" colspan="1">0.837</td><td align="left" rowspan="1" colspan="1">0.243</td><td align="left" rowspan="1" colspan="1">0.725</td><td align="left" rowspan="1" colspan="1">0.441</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Belo Horizonte</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">25%</td><td align="left" rowspan="1" colspan="1">0.868</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.726</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;BH Border towns</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">15%</td><td align="left" rowspan="1" colspan="1">0.862</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.736</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other municipalities which make up the Metropolitan Region of BH</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">19%</td><td align="left" rowspan="1" colspan="1">0.886</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.666</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Education level</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Illiterate</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">6%</td><td align="left" rowspan="1" colspan="1">0.742</td><td align="left" rowspan="1" colspan="1">0.016*</td><td align="left" rowspan="1" colspan="1">0.642</td><td align="left" rowspan="1" colspan="1">0.800</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Middle School</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">42%</td><td align="left" rowspan="1" colspan="1">0.854</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.713</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;High School</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">29%</td><td align="left" rowspan="1" colspan="1">0.875</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.717</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Higher education</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">17%</td><td align="left" rowspan="1" colspan="1">0.908</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.732</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Not reported</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">7%</td><td align="left" rowspan="1" colspan="1">0.784</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Economic class</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;AB</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">20%</td><td align="left" rowspan="1" colspan="1">0.911</td><td align="left" rowspan="1" colspan="1">0.070</td><td align="left" rowspan="1" colspan="1">0.725</td><td align="left" rowspan="1" colspan="1">0.943</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;C</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">41%</td><td align="left" rowspan="1" colspan="1">0.852</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.708</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DE</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">40%</td><td align="left" rowspan="1" colspan="1">0.838</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.720</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity?</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">39%</td><td align="left" rowspan="1" colspan="1">0.887</td><td align="left" rowspan="1" colspan="1">0.063</td><td align="left" rowspan="1" colspan="1">0.742</td><td align="left" rowspan="1" colspan="1">0.440</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">60%</td><td align="left" rowspan="1" colspan="1">0.842</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.700</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Not reported</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1%</td><td align="left" rowspan="1" colspan="1">0.572</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.636</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Alcoholic?</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">42%</td><td align="left" rowspan="1" colspan="1">0.830</td><td align="left" rowspan="1" colspan="1">0.293</td><td align="left" rowspan="1" colspan="1">0.688</td><td align="left" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">52%</td><td align="left" rowspan="1" colspan="1">0.883</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.741</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Not reported</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">6%</td><td align="left" rowspan="1" colspan="1">0.840</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.696</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Drug user?</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="left" rowspan="1" colspan="1">124</td><td align="left" rowspan="1" colspan="1">87%</td><td align="left" rowspan="1" colspan="1">0.853</td><td align="left" rowspan="1" colspan="1">0.254</td><td align="left" rowspan="1" colspan="1">0.713</td><td align="left" rowspan="1" colspan="1">0.854</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">7%</td><td align="left" rowspan="1" colspan="1">0.933</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Not reported</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">6%</td><td align="left" rowspan="1" colspan="1">0.839</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.710</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">New case?</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">12%</td><td align="left" rowspan="1" colspan="1">0.848</td><td align="left" rowspan="1" colspan="1">0.530</td><td align="left" rowspan="1" colspan="1">0.674</td><td align="left" rowspan="1" colspan="1">0.271</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="left" rowspan="1" colspan="1">126</td><td align="left" rowspan="1" colspan="1">88%</td><td align="left" rowspan="1" colspan="1">0.859</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.722</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Previous treatment</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="left" rowspan="1" colspan="1">121</td><td align="left" rowspan="1" colspan="1">85%</td><td align="left" rowspan="1" colspan="1">0.855</td><td align="left" rowspan="1" colspan="1">0.742</td><td align="left" rowspan="1" colspan="1">0.721</td><td align="left" rowspan="1" colspan="1">0.351</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">15%</td><td align="left" rowspan="1" colspan="1">0.873</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.689</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Clinical form</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cutaneous leishmaniasis</td><td align="left" rowspan="1" colspan="1">116</td><td align="left" rowspan="1" colspan="1">81%</td><td align="left" rowspan="1" colspan="1">0.865</td><td align="left" rowspan="1" colspan="1">0.270</td><td align="left" rowspan="1" colspan="1">0.718</td><td align="left" rowspan="1" colspan="1">0.353</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mucous leishmaniasis</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">11%</td><td align="left" rowspan="1" colspan="1">0.805</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.686</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cutaneous and mucosal leishmaniasis</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">8%</td><td align="left" rowspan="1" colspan="1">0.854</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.742</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lesion area</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lower limbs</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46%</td><td align="left" rowspan="1" colspan="1">0.882</td><td align="left" rowspan="1" colspan="1">0.866</td><td align="left" rowspan="1" colspan="1">0.709</td><td align="left" rowspan="1" colspan="1">0.547</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Upper limbs</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">22%</td><td align="left" rowspan="1" colspan="1">0.835</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.718</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Head</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">15%</td><td align="left" rowspan="1" colspan="1">0.853</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.746</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mucous</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">11%</td><td align="left" rowspan="1" colspan="1">0.805</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.686</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Trunk</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">6%</td><td align="left" rowspan="1" colspan="1">0.861</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.748</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Legend: N: number of participants. CL: cutaneous leishmaniasis.</p></fn></table-wrap-foot></table-wrap><p>Most patients had the cutaneous form of leishmaniasis, including ten patients with the disseminated cutaneous form (more than six skin lesions). A total of 17 recurrences were identified, mostly in the cutaneous form, while the remaining 126 patients corresponded to new cases (new lesions, even if others had been previously treated). Among the 17 patients who experienced recurrence, six had previously undergone treatment, indicating failure of the initial therapy. In most cases, the lesions were located on the limbs. Regarding clinical characteristics, 86 patients had some concomitant disease (such as hypertension or diabetes) at the time of CL diagnosis, 20 of whom were not receiving treatment for comorbidities. Overall, the utility values were similar across the assessed categories, considering the clinical and sociodemographic characteristics of the participants. Before the onset of CL symptoms, a significant difference (p&#x02009;&#x0003c;&#x02009;0.05) in mean utility was observed for education level. The only significant difference for average utility observed in patients with active disease was for sex (p&#x02009;&#x0003c;&#x02009;0.001).</p><p>Before the onset of CL symptoms, the average utility was 0.858, showing a significant reduction to 0.716 after the symptoms manifested (a loss of 16.6%, p&#x02009;&#x0003c;&#x02009;0,0001) (<bold><xref rid="pone.0324788.t002" ref-type="table">Table 2</xref></bold>). The VAS results support the magnitude of this loss, with the average score reported by patients before CL being 87 and decreasing to 70 during active CL, representing a loss of 19.5% (p&#x02009;&#x0003c;&#x02009;0.001).</p><table-wrap position="float" id="pone.0324788.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0324788.t002</object-id><label>Table 2</label><caption><title>Proportion of individuals in each dimension and level of impact of the EQ-5D-3L scale before symptoms and with active cutaneous leishmaniasis.</title></caption><alternatives><graphic xlink:href="pone.0324788.t002" id="pone.0324788.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1">EQ-5D dimensions</th><th align="left" rowspan="3" colspan="1">Moment</th><th align="left" colspan="7" rowspan="1">Intensity levels</th><th align="left" rowspan="1" colspan="1"/></tr><tr><th align="left" colspan="3" rowspan="1">No problems</th><th align="left" colspan="2" rowspan="1">Some problems</th><th align="left" colspan="2" rowspan="1">Extreme problems</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p-value</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1">n</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">Difference* %</th><th align="left" rowspan="1" colspan="1">n (%)</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">n (%)</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">
<bold>Mobility</bold>
</td><td align="left" rowspan="1" colspan="1">Before CL</td><td align="left" rowspan="1" colspan="1">133</td><td align="left" rowspan="1" colspan="1">93.0</td><td align="left" rowspan="1" colspan="1">17.3</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">6.3</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="2" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Active CL</td><td align="left" rowspan="1" colspan="1">110</td><td align="left" rowspan="1" colspan="1">76.9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">22.4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Self-care</bold>
</td><td align="left" rowspan="1" colspan="1">Before CL</td><td align="left" rowspan="1" colspan="1">142</td><td align="left" rowspan="1" colspan="1">99.3</td><td align="left" rowspan="1" colspan="1">15.5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="2" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Active CL</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">83.9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">15.4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Habitual activities</bold>
</td><td align="left" rowspan="1" colspan="1">Before CL</td><td align="left" rowspan="1" colspan="1">138</td><td align="left" rowspan="1" colspan="1">96.5</td><td align="left" rowspan="1" colspan="1">26.8</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="2" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Active CL</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">70.6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">26.6</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Pain/malaise</bold>
</td><td align="left" rowspan="1" colspan="1">Before CL</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">60.1</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">35.7</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">4.2</td><td align="left" rowspan="2" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Active CL</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">30.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">63.6</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">6.3</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Anxiety/depression</bold>
</td><td align="left" rowspan="1" colspan="1">Before CL</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">70.6</td><td align="left" rowspan="1" colspan="1">22.8</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">23.8</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">5.6</td><td align="left" rowspan="2" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Active CL</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">54.5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">32.2</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">13.3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Scale</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" colspan="2" rowspan="1">
<bold>Average score (&#x000b1;SD)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x02013;</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>EQ-VAS</bold>
</td><td align="left" rowspan="1" colspan="1">Before CL</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">(14.7)</td><td align="left" rowspan="1" colspan="1">19.5</td><td align="left" rowspan="1" colspan="1">
<bold>&#x02013;</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>&#x02013;</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="2" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Active CL</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">(21.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>EQ-5D Utility</bold>
</td><td align="left" rowspan="1" colspan="1">Before CL</td><td align="left" rowspan="1" colspan="1">0.858</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">16.6</td><td align="left" rowspan="1" colspan="1">
<bold>&#x02013;</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>&#x02013;</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="2" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Active CL</td><td align="left" rowspan="1" colspan="1">0.716</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Legend: CL: cutaneous leishmaniasis; EQ-VAS: Visual Analogue Scale; SD: Standard Deviation.</p></fn><fn id="t002fn002"><p>* Percentage difference which takes &#x0201c;Before CL&#x0201d; as 100%.</p></fn></table-wrap-foot></table-wrap><p>When each dimension of the EQ-5D was analyzed before CL onset, more than half of the participants reported &#x0201c;no problems&#x0201d; across all dimensions (<bold><xref rid="pone.0324788.g001" ref-type="fig">Fig 1</xref></bold>). Following the manifestation of CL, all EQ-5D dimensions were impacted, particularly those related to pain and discomfort, as well as usual activities, where the proportion of patients reporting no issues decreased by 50% and 27%, respectively (<bold><xref rid="pone.0324788.g001" ref-type="fig">Fig 1</xref></bold> and <bold><xref rid="pone.0324788.t002" ref-type="table">Table 2</xref></bold>).</p><fig position="float" id="pone.0324788.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0324788.g001</object-id><label>Fig 1</label><caption><title>Proportion of problems intensity in each dimension according to the EQ-5D-3L scale before symptoms and with active cutaneous leishmaniasis.</title><p>Legend: CL: cutaneous leishmaniasis.</p></caption><graphic xlink:href="pone.0324788.g001" position="float"/></fig><p><bold><xref rid="pone.0324788.t003" ref-type="table">Table 3</xref></bold> presents the distributions of health states before CL onset and during the active disease phase. Prior to illness, the most common health states were those without issues in most dimensions (11111, 11121, and 11112, representing 46%, 20%, and 13%, respectively). After the onset of illness, the proportion of responses indicating no problems across all dimensions (11111) decreased to second place (16%), whereas state 11121 rose to first place (20%), and state 11122 came in third place (14%). In this last state, patients reported some issues in the dimensions of pain/discomfort and anxiety/depression, indicating a decline in the perceived health of this population.</p><table-wrap position="float" id="pone.0324788.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0324788.t003</object-id><label>Table 3</label><caption><title>Distribution of EQ-5D-3L health states of patients before symptoms and with active cutaneous leishmaniasis.</title></caption><alternatives><graphic xlink:href="pone.0324788.t003" id="pone.0324788.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Health states</th><th align="left" colspan="2" rowspan="1">Before CL</th><th align="left" colspan="2" rowspan="1">Active CL</th></tr><tr><th align="left" rowspan="1" colspan="1">N</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">N</th><th align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">11111</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">0,462</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">0,161</td></tr><tr><td align="left" rowspan="1" colspan="1">11112</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">0,126</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">0,063</td></tr><tr><td align="left" rowspan="1" colspan="1">11121</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">0,203</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">0,203</td></tr><tr><td align="left" rowspan="1" colspan="1">11122</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">0,063</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">0,140</td></tr><tr><td align="left" rowspan="1" colspan="1">11123</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0,021</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">11131</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0,014</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">11132</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td></tr><tr><td align="left" rowspan="1" colspan="1">11133</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td></tr><tr><td align="left" rowspan="1" colspan="1">11211</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">11212</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0,014</td></tr><tr><td align="left" rowspan="1" colspan="1">11221</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">11222</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0,028</td></tr><tr><td align="left" rowspan="1" colspan="1">11223</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0,014</td></tr><tr><td align="left" rowspan="1" colspan="1">11232</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td></tr><tr><td align="left" rowspan="1" colspan="1">11233</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0,028</td></tr><tr><td align="left" rowspan="1" colspan="1">12121</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0,014</td></tr><tr><td align="left" rowspan="1" colspan="1">12122</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">12123</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">12211</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">12213</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">12221</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0,035</td></tr><tr><td align="left" rowspan="1" colspan="1">12222</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">12223</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">21111</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td></tr><tr><td align="left" rowspan="1" colspan="1">21112</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0,014</td></tr><tr><td align="left" rowspan="1" colspan="1">21113</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">21121</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0,035</td></tr><tr><td align="left" rowspan="1" colspan="1">21122</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0,021</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">21123</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0,014</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0,021</td></tr><tr><td align="left" rowspan="1" colspan="1">21133</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">21211</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0,014</td></tr><tr><td align="left" rowspan="1" colspan="1">21221</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0,021</td></tr><tr><td align="left" rowspan="1" colspan="1">21222</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0,014</td></tr><tr><td align="left" rowspan="1" colspan="1">21232</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">21322</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">21332</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">22121</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">22221</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0,021</td></tr><tr><td align="left" rowspan="1" colspan="1">22222</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">22223</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0,021</td></tr><tr><td align="left" rowspan="1" colspan="1">23311</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">32333</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td></tr><tr><td align="left" rowspan="1" colspan="1">33123</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0,007</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0,000</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>Legend: N = number of participants; CL= cutaneous leishmaniasis</p></fn></table-wrap-foot></table-wrap><p>The cumulative distribution of ordered utilities, ranging from the best to the worst health state, according to their respective utility values before and after active CL, is illustrated in <bold><xref rid="pone.0324788.g002" ref-type="fig">Fig 2</xref></bold>. The greater proportion of participants with better health states before illness is evident, as the curve for the period before CL is positioned above the curve for active CL. The difference between the curves highlights the loss of QoL associated with active CL, with the curve representing active CL reaching 100% more slowly, reflecting the presence of patients with poorer health states.</p><fig position="float" id="pone.0324788.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0324788.g002</object-id><label>Fig 2</label><caption><title>Cumulative distribution of EQ-5D-3L utilities decreasingly ordered before and after the onset of cutaneous leishmaniasis symptoms.</title><p>Legend: CL: cutaneous leishmaniasis.</p></caption><graphic xlink:href="pone.0324788.g002" position="float"/></fig></sec><sec sec-type="conclusions" id="sec007"><title>Discussion</title><p>QALYs have been increasingly valued as a health outcome parameter in public policy decision-making because of their comprehensiveness and legitimacy in reflecting patients&#x02019; perspectives on their well-being. It adds valuable information to the benefit of &#x0201c;years of life gained&#x0201d; from a given intervention. In Brazil, this emphasis is articulated in the Ministry of Health&#x02019;s Economic Evaluation Guidelines, which establish cost&#x02012;utility assessments as preferred methods to support decision-making regarding the incorporation of health technologies [<xref rid="pone.0324788.ref029" ref-type="bibr">29</xref>]. Previous studies have shown that CL impacts the QoL of affected individuals; however, a score for use in economic analysis has not yet been developed [<xref rid="pone.0324788.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0324788.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0324788.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0324788.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pone.0324788.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0324788.ref030" ref-type="bibr">30</xref>]. In the present study, utility values for CL were achieved, enabling the future adoption of the QALYs benchmark in economic analyses of interventions for the disease.</p><p>These results indicate that the average health utility of CL patients is significantly affected by the disease. Before the onset of symptoms, participants reported an average utility of 0.858, which decreased to 0.716 during active CL. This decline aligns with findings from other studies of dermatological diseases, such as leishmaniasis, which have reported a reduction in QoL associated with various dermatologic health conditions. For instance, a European multicenter study showed lower mean VAS scores (69.9) than controls (82.2), in patients with various skin diseases [<xref rid="pone.0324788.ref031" ref-type="bibr">31</xref>]. Another study conducted in Vietnam assessed the impact of different skin conditions on HRQoL and found an overall mean utility score of 0.73, with the largest subgroup consisting of patients with atopic or contact dermatitis [<xref rid="pone.0324788.ref032" ref-type="bibr">32</xref>]. In Brazil, research on herpes zoster, a dermatological condition characterized associated with significant pain, demonstrated a decline in QoL, with utility scores dropping to 0.7 after symptoms onset [<xref rid="pone.0324788.ref033" ref-type="bibr">33</xref>]. These findings indicate that the decrease in HRQoL observed in CL is consistent with that seen in other skin diseases.</p><p>The present study revealed that CL impacts all the assessed domains of the EQ-5D, identifying &#x0201c;pain and discomfort&#x0201d; as the most affected dimension, characterized by the highest number of reports of &#x0201c;some problems&#x0201d; or &#x0201c;extreme issues&#x0201d; and the greatest difference compared to the period before symptom onset. Although CL typically presents as painless ulcers [<xref rid="pone.0324788.ref034" ref-type="bibr">34</xref>&#x02013;<xref rid="pone.0324788.ref036" ref-type="bibr">36</xref>], other studies on CL support this finding, indicating a greater impact of CL on similar dimensions of the DLQI, such as &#x0201c;symptoms and feelings&#x0201d; [<xref rid="pone.0324788.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0324788.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0324788.ref030" ref-type="bibr">30</xref>] (understood as discomfort or embarrassment caused by the wound) [<xref rid="pone.0324788.ref037" ref-type="bibr">37</xref>] and specific complaints of pain [<xref rid="pone.0324788.ref003" ref-type="bibr">3</xref>]. This dimension, along with self-care (in the European study) and anxiety/depression (in Vietnamese patients), was also one of the most affected in studies addressing other skin diseases in Europe and Vietnam [<xref rid="pone.0324788.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0324788.ref032" ref-type="bibr">32</xref>], reinforcing the importance of incorporating pain management, psychological support, and patient-centered care into clinical management.</p><p>Although this study did not find a significant difference in utilities across different lesion locations, lesions that visibly affect appearance may cause some stigma, whereas lesions on limbs may interfere with usual activities. Studies such as that conducted by Hu et al. (2020) [<xref rid="pone.0324788.ref022" ref-type="bibr">22</xref>] in Suriname have shown that lesions located on the lower limbs have a greater impact on HRQoL, particularly in the dimensions of self-care, mobility, usual activities, and pain and discomfort, than lesions on other parts of the body do. Facial lesions have also been associated with lower HRQoL [<xref rid="pone.0324788.ref016" ref-type="bibr">16</xref>] and greater psychosocial impact [<xref rid="pone.0324788.ref021" ref-type="bibr">21</xref>].</p><p>Another dimension significantly affected by CL in this study, as corroborated by other authors [<xref rid="pone.0324788.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0324788.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0324788.ref017" ref-type="bibr">17</xref>], is the ability to perform usual activities, such as working, studying, taking care of the household, meeting friends and neighbors, and attending churches. The impact on this dimension can be reflected in both the income of patients and their families, who are often already facing socio-economic disadvantages.</p><p>[<xref rid="pone.0324788.ref013" ref-type="bibr">13</xref>], as well as in psychosocial aspects (mental health issues and psychosocial morbidity). Some authors emphasize the importance of improving patient communication to clarify misunderstandings about the disease, which can lead to psychosocial impacts and unnecessary absences from work or school [<xref rid="pone.0324788.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0324788.ref018" ref-type="bibr">18</xref>].</p><p>Anxiety and depression are also evident in the current study population, as demonstrated in previous studies [<xref rid="pone.0324788.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0324788.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0324788.ref021" ref-type="bibr">21</xref>]. These conditions represented the second dimension with the highest reports of any problems or extreme problems among patients with active CL. Notably, depression is a factor affecting HRQoL in patients with chronic diseases [<xref rid="pone.0324788.ref038" ref-type="bibr">38</xref>&#x02013;<xref rid="pone.0324788.ref040" ref-type="bibr">40</xref>], and more than half of the participants in the present study had some comorbidities.</p><p>In this study, a significant difference was observed in the self-reported utility of participants, prior to disease onset, with respect to educational level, since higher educational attainment is generally associated with better economic status access to healthcare, greater financial stability, and improved overall well-being. This difference aligns with expectations and is consistent with previous studies, which has shown a correlation between higher educational attainment, employment rate, family income, and improved quality of life. [<xref rid="pone.0324788.ref041" ref-type="bibr">41</xref>,<xref rid="pone.0324788.ref042" ref-type="bibr">42</xref>]. Among patients with an active skin disease, sex was the only variable that showed a significant difference, indicating that women reported a lower perception of quality of life compared to men. This finding is consistent with studies on patients with other skin conditions. A possible explanation is that physical appearance tends to be a more sensitive concern for women than for men, and skin diseases may therefore lead to greater psychological distress among women [<xref rid="pone.0324788.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0324788.ref043" ref-type="bibr">43</xref>&#x02013;<xref rid="pone.0324788.ref045" ref-type="bibr">45</xref>].</p><p>This study has some limitations. The first relates to the use of generic instruments. The EQ-5D, although widely validated and useful for comparisons across different health conditions, may not capture all the nuances and particularities of CL. Despite this limitation, the instrument proved sensitive in measuring the loss of HRQoL with the onset of CL symptoms. This sensitivity was corroborated by evaluating patients via the VAS, as the magnitude of loss was similar. A second limitation pertains to the use of retrospective measures. Since patients were only monitored when they sought healthcare services due to symptoms of the disease, health states prior to the disease were lacking. Therefore, it was necessary to use retrospective measures to address this limitation, which may be subject to memory issues and changes in individuals&#x02019; perceptions of their past health due to the disease&#x02019;s impact on their health [<xref rid="pone.0324788.ref046" ref-type="bibr">46</xref>,<xref rid="pone.0324788.ref047" ref-type="bibr">47</xref>]. Various studies [<xref rid="pone.0324788.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0324788.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0324788.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0324788.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pone.0324788.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0324788.ref030" ref-type="bibr">30</xref>], including those using the EQ-5D, have employed retrospective health measures to evaluate losses resulting from health impacts.</p><p>Additionally, a third limitation is that the inclusion of patients across a wide age range, from adolescents to elderly individuals, may introduce variability in responses, particularly in dimensions such as mobility and self-care. However, no significant differences in utility values were observed between age categories, suggesting a consistent impact of CL on HRQoL across different age groups. Nonetheless, given that baseline expectations for these domains differ significantly by age, comparisons of HRQoL loss between younger and older participants should be interpreted with caution.</p><p>The fourth limitation is related to the study design, which involved individuals from the health center conducting the interviews. Conducting the interviews at the same health center where patients receive care may introduce bias in the responses, often referred to as &#x0201c;gratitude bias&#x0201d; [<xref rid="pone.0324788.ref048" ref-type="bibr">48</xref>&#x02013;<xref rid="pone.0324788.ref050" ref-type="bibr">50</xref>]. Patients may report exaggerated improvements in their QoL owing to the perception that this will please the interviewer or because they wish to be seen as cooperative.</p><p>Finally, this study may not fully represent the broader population affected by CL because it was conducted in a CL referral center, which may introduce a selection bias of more severe cases. In addition, it was based on a convenience sample rather than being derived from a calculated sample size. Patients were included based on their access to healthcare services and the availability of the researchers involved. The sample could be considered small and may lack sufficient diversity in terms of age, gender, socioeconomic status, and geographical location.</p><p>In the context of neglected diseases, the assessment of HRQoL is especially relevant, as it disproportionately affects poor and marginalized populations, increasing their susceptibility to worsening living conditions. QoL assessments can highlight the hidden burden of these diseases and justify the allocation of more resources for their control [<xref rid="pone.0324788.ref051" ref-type="bibr">51</xref>,<xref rid="pone.0324788.ref052" ref-type="bibr">52</xref>]. However, the same limitations discussed earlier apply, and the need for culturally sensitive and specific assessment tools is even more pressing.</p><p>The use of the EQ-5D in this study provided valuable insights into the impact of CL on patients&#x02019; HRQoL. By generating utility measures, these findings contribute to future cost-utility analyses, allowing for evidence-based comparisons of health technologies for CL management. Moreover, this study reinforces the need for public health strategies that go beyond clinical treatment, incorporating interventions aimed at mitigating the psychosocial and economic burden of CL, particularly in vulnerable populations. From a policy perspective, these results highlight the importance of integrating HRQoL assessments into health decision-making processes, ensuring that resource allocation and intervention prioritization consider not only disease outcomes but also patient well-being. To enhance the impact of such evaluations, future research should focus on refining assessment methodologies including the development of disease-specific utility-based instruments for more precise CL impact measurement, the improvement of data collection strategy to minimize recall bias, and the enhancement of generic instruments to better capture stigma and mental health effects. Furthermore, it is essential to prioritize expanding sample representativeness and addressing identified methodological limitations to strengthen the applicability of HRQoL data in public health decision-making and policy planning.</p></sec><sec id="sec008" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0324788.s001" position="float" content-type="local-data"><label>S1 Appendix</label><caption><title>EQ-5D-3L &#x02013; CURRENT health status (Active CL).</title><p>(DOCX)</p></caption><media xlink:href="pone.0324788.s001.docx"/></supplementary-material><supplementary-material id="pone.0324788.s002" position="float" content-type="local-data"><label>S2 Appendix</label><caption><title>EQ-5D-3L &#x02013; RETROSPECTIVE health status (before CL).</title><p>(DOCX)</p></caption><media xlink:href="pone.0324788.s002.docx"/></supplementary-material><supplementary-material id="pone.0324788.s003" position="float" content-type="local-data"><label>S3 Appendix</label><caption><title>Socioeconomic questionnaire.</title><p>(DOCX)</p></caption><media xlink:href="pone.0324788.s003.docx"/></supplementary-material></sec></body><back><ack><p>The authors would like to thank the Instituto Ren&#x000e9; Rachou, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior (CAPES), Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico (CNPq), Centro Federal de Educa&#x000e7;&#x000e3;o Tecnol&#x000f3;gica de Minas Gerais and Universidade Federal dos Vales do Jequitinhonha e Mucuri.</p></ack><ref-list><title>References</title><ref id="pone.0324788.ref001"><label>1</label><mixed-citation publication-type="other">Ruiz-Postigo JA, Jain S, Madjou S, Maia-Elkhoury AN, Valadas S, Warusavithana S, et al. Global leishmaniasis surveillance, 2022: assessing trends over the past 10 years. 2023.</mixed-citation></ref><ref id="pone.0324788.ref002"><label>2</label><mixed-citation publication-type="journal"><collab>OPAS OP-A da S</collab>. Leishmanioses: Informe epidemiol&#x000f3;gico das Am&#x000e9;ricas. N&#x000fa;m. 12 (Dezembro de 2023). <year>2024</year>;<fpage>14</fpage>. Available: <ext-link xlink:href="https://iris.paho.org/handle/10665.2/59170" ext-link-type="uri">https://iris.paho.org/handle/10665.2/59170</ext-link></mixed-citation></ref><ref id="pone.0324788.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>de Melo Hon&#x000f3;rio</surname><given-names>I</given-names></name>, <name><surname>Utzig Cossul</surname><given-names>M</given-names></name>, <name><surname>Neves da Silva Bampi</surname><given-names>L</given-names></name>, <name><surname>Baraldi</surname><given-names>S</given-names></name>. <article-title>Qualidade de vida em pessoas com leishmaniose cut&#x000e2;nea</article-title>. <source>RBPS</source>. <year>2016</year>;<volume>29</volume>(<issue>3</issue>):<fpage>342</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5020/18061230.2016.p342</pub-id></mixed-citation></ref><ref id="pone.0324788.ref004"><label>4</label><mixed-citation publication-type="book"><collab>OPAS OP-A da S, OMS OM da S. Leishmanioses</collab>. Informe Epidemiol&#x000f3;gico das Am&#x000e9;ricas, dezembro 2021. <publisher-loc>Leishmaniases</publisher-loc>: <publisher-name>Epidemiological Report of the Americas</publisher-name>. <year>2021</year>;<fpage>10</fpage>. Available: <ext-link xlink:href="https://iris.paho.org/handle/10665.2/55386" ext-link-type="uri">https://iris.paho.org/handle/10665.2/55386</ext-link></mixed-citation></ref><ref id="pone.0324788.ref005"><label>5</label><mixed-citation publication-type="journal"><collab>The WHOQOL Group</collab>. <article-title>The World Health Organization quality of life assessment (WHOQOL): Position paper from the World Health Organization</article-title>. <source>Soc Sci Med</source>. <year>1995</year>;<volume>41</volume>(<issue>10</issue>):<fpage>1403</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0277-9536(95)00112-k</pub-id>
<pub-id pub-id-type="pmid">8560308</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Karimi</surname><given-names>M</given-names></name>, <name><surname>Brazier</surname><given-names>J</given-names></name>. <article-title>Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?</article-title>. <source>Pharmacoeconomics</source>. <year>2016</year>;<volume>34</volume>(<issue>7</issue>):<fpage>645</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s40273-016-0389-9</pub-id>
<pub-id pub-id-type="pmid">26892973</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Pequeno</surname><given-names>NPF</given-names></name>, <name><surname>Cabral NL de</surname><given-names>A</given-names></name>, <name><surname>Marchioni</surname><given-names>DM</given-names></name>, <name><surname>Lima</surname><given-names>SCVC</given-names></name>, <name><surname>Lyra C de</surname><given-names>O</given-names></name>. <article-title>Quality of life assessment instruments for adults: a systematic review of population-based studies</article-title>. <source>Health Qual Life Outcomes</source>. <year>2020</year>;<volume>18</volume>(<issue>1</issue>):<fpage>208</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12955-020-01347-7</pub-id>
<pub-id pub-id-type="pmid">32605649</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Andrade</surname><given-names>MV</given-names></name>, <name><surname>Noronha</surname><given-names>K</given-names></name>, <name><surname>Guedes</surname><given-names>GR</given-names></name>, <name><surname>Diniz</surname><given-names>BC</given-names></name>, <name><surname>Silva</surname><given-names>VA</given-names></name>, <name><surname>de Souza</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Health-related quality of life due to malaria: a systematic review</article-title>. <source>Qual Life Res</source>. <year>2025</year>;<volume>34</volume>(<issue>2</issue>):<fpage>325</fpage>&#x02013;<lpage>39</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11136-024-03822-w</pub-id>
<pub-id pub-id-type="pmid">39503941</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Scattolin</surname><given-names>FA de A</given-names></name>. <article-title>Qualidade de vida: a evolu&#x000e7;&#x000e3;o do conceito e os instrumentos de medida</article-title>. <source>Rev Fac Cien Med Sorocaba</source>. <year>2007</year>;<volume>8</volume>:<fpage>1</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0324788.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Bezemer</surname><given-names>JM</given-names></name>, <name><surname>Hinojosa</surname><given-names>MC</given-names></name>, <name><surname>Zabala</surname><given-names>AEC</given-names></name>, <name><surname>P&#x000e9;rez</surname><given-names>FO</given-names></name>, <name><surname>Rom&#x000e1;n</surname><given-names>VCV</given-names></name>, <name><surname>Schallig</surname><given-names>HDFH</given-names></name>, <etal>et al</etal>. <article-title>Quality of life of cutaneous leishmaniasis suspected patients in the Ecuadorian Pacific and Amazon regions: a cross sectional study</article-title>. <source>BMC Infect Dis</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>748</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12879-022-07733-4</pub-id>
<pub-id pub-id-type="pmid">36153487</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Carvalho</surname><given-names>CDP</given-names></name>, <name><surname>Luz</surname><given-names>JGG</given-names></name>, <name><surname>Carvalho AG</surname><given-names>de</given-names></name>, <name><surname>Carvalho</surname><given-names>RDP</given-names></name>, <name><surname>Pires</surname><given-names>HHR</given-names></name>, <name><surname>Dias</surname><given-names>JVL</given-names></name>. <article-title>&#x0201c;It&#x02019;s not all about the disease&#x0201d;: do treatment and socioeconomic status affect perceived impact and satisfaction of patients treated for cutaneous leishmaniasis?</article-title>. <source>Rev Soc Bras Med Trop</source>. <year>2023</year>;<volume>56</volume>:e0253. <comment>doi: </comment><pub-id pub-id-type="doi">10.1590/0037-8682-0253-2022</pub-id>
<pub-id pub-id-type="pmid">36820654</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Galv&#x000e3;o</surname><given-names>EL</given-names></name>, <name><surname>Assis TSM</surname><given-names>de</given-names></name>, <name><surname>Pedras</surname><given-names>MJ</given-names></name>, <name><surname>Cota</surname><given-names>GF</given-names></name>, <name><surname>Sim&#x000f5;es</surname><given-names>TC</given-names></name>, <name><surname>Rabello</surname><given-names>A</given-names></name>. <article-title>Economic impact of localized cutaneous leishmaniasis on adult patients of a referral service in Belo Horizonte, Minas Gerais State, Brazil</article-title>. <source>Cad Saude Publica</source>. <year>2020</year>;<volume>36</volume>(<issue>7</issue>):e00136419. <comment>doi: </comment><pub-id pub-id-type="doi">10.1590/0102-311x00136419</pub-id>
<pub-id pub-id-type="pmid">32696829</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Mashayekhi-Ghoyonlo</surname><given-names>V</given-names></name>, <name><surname>Kiafar</surname><given-names>B</given-names></name>, <name><surname>Rohani</surname><given-names>M</given-names></name>, <name><surname>Esmaeili</surname><given-names>H</given-names></name>, <name><surname>Erfanian-Taghvaee</surname><given-names>MR</given-names></name>. <article-title>Correlation between Socioeconomic Status and Clinical Course in Patients with Cutaneous Leishmaniasis</article-title>. <source>J Cutan Med Surg</source>. <year>2015</year>;<volume>19</volume>(<issue>1</issue>):<fpage>40</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2310/7750.2014.13216</pub-id>
<pub-id pub-id-type="pmid">25775662</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Erber</surname><given-names>AC</given-names></name>, <name><surname>Arana</surname><given-names>B</given-names></name>, <name><surname>Ben Salah</surname><given-names>A</given-names></name>, <name><surname>Bennis</surname><given-names>I</given-names></name>, <name><surname>Boukthir</surname><given-names>A</given-names></name>, <name><surname>Castro Noriega</surname><given-names>MDM</given-names></name>, <etal>et al</etal>. <article-title>Patients&#x02019; preferences of cutaneous leishmaniasis treatment outcomes: Findings from an international qualitative study</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2020</year>;<volume>14</volume>(<issue>2</issue>):e0007996. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0007996</pub-id>
<pub-id pub-id-type="pmid">32092059</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Galv&#x000e3;o</surname><given-names>EL</given-names></name>, <name><surname>Pedras</surname><given-names>MJ</given-names></name>, <name><surname>Cota</surname><given-names>GF</given-names></name>, <name><surname>Rabello</surname><given-names>A</given-names></name>, <name><surname>Sim&#x000f5;es</surname><given-names>TC</given-names></name>. <article-title>How cutaneous leishmaniasis and treatment impacts in the patients&#x02019; lives: A cross-sectional study</article-title>. <source>PLoS One</source>. <year>2019</year>;<volume>14</volume>(<issue>1</issue>):e0211374. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0211374</pub-id>
<pub-id pub-id-type="pmid">30682151</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Ranawaka</surname><given-names>RR</given-names></name>, <name><surname>Weerakoon</surname><given-names>HS</given-names></name>, <name><surname>de Silva</surname><given-names>SH</given-names></name>. <article-title>The quality of life of Sri Lankan patients with cutaneous leishmaniasis</article-title>. <source>Mymensingh Med J</source>. <year>2014</year>;<volume>23</volume>(<issue>2</issue>):<fpage>345</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="pmid">24858165</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Toledo AC de C</surname><given-names>Jr</given-names></name>, <name><surname>da Silva</surname><given-names>RE</given-names></name>, <name><surname>Carmo</surname><given-names>RF</given-names></name>, <name><surname>Amaral</surname><given-names>TA</given-names></name>, <name><surname>Luz</surname><given-names>ZMP</given-names></name>, <name><surname>Rabello</surname><given-names>A</given-names></name>. <article-title>Assessment of the quality of life of patients with cutaneous leishmaniasis in Belo Horizonte, Brazil, 2009-2010. A pilot study</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2013</year>;<volume>107</volume>(<issue>5</issue>):<fpage>335</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/trstmh/trt021</pub-id>
<pub-id pub-id-type="pmid">23474473</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Boukthir</surname><given-names>A</given-names></name>, <name><surname>Bettaieb</surname><given-names>J</given-names></name>, <name><surname>Erber</surname><given-names>AC</given-names></name>, <name><surname>Bouguerra</surname><given-names>H</given-names></name>, <name><surname>Mallekh</surname><given-names>R</given-names></name>, <name><surname>Naouar</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Psycho-social impacts, experiences and perspectives of patients with Cutaneous Leishmaniasis regarding treatment options and case management: An exploratory qualitative study in Tunisia</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>12</issue>):e0242494. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0242494</pub-id>
<pub-id pub-id-type="pmid">33259489</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Pires</surname><given-names>M</given-names></name>, <name><surname>Wright</surname><given-names>B</given-names></name>, <name><surname>Kaye</surname><given-names>PM</given-names></name>, <name><surname>da Concei&#x000e7;&#x000e3;o</surname><given-names>V</given-names></name>, <name><surname>Churchill</surname><given-names>RC</given-names></name>. <article-title>The impact of leishmaniasis on mental health and psychosocial well-being: A systematic review</article-title>. <source>PLoS One</source>. <year>2019</year>;<volume>14</volume>(<issue>10</issue>):e0223313. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0223313</pub-id>
<pub-id pub-id-type="pmid">31622369</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Turan</surname><given-names>E</given-names></name>, <name><surname>Kandemir</surname><given-names>H</given-names></name>, <name><surname>Ye&#x0015f;ilova</surname><given-names>Y</given-names></name>, <name><surname>Ekinci</surname><given-names>S</given-names></name>, <name><surname>Tanr&#x00131;kulu</surname><given-names>O</given-names></name>, <name><surname>Kandemir</surname><given-names>SB</given-names></name>, <etal>et al</etal>. <article-title>Assessment of psychiatric morbidity and quality of life in children and adolescents with cutaneous leishmaniasis and their parents</article-title>. <source>Postepy Dermatol Alergol</source>. <year>2015</year>;<volume>32</volume>(<issue>5</issue>):<fpage>344</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5114/pdia.2015.54744</pub-id>
<pub-id pub-id-type="pmid">26759542</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Yanik</surname><given-names>M</given-names></name>, <name><surname>Gurel</surname><given-names>MS</given-names></name>, <name><surname>Simsek</surname><given-names>Z</given-names></name>, <name><surname>Kati</surname><given-names>M</given-names></name>. <article-title>The psychological impact of cutaneous leishmaniasis</article-title>. <source>Clin Exp Dermatol</source>. <year>2004</year>;<volume>29</volume>(<issue>5</issue>):<fpage>464</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1365-2230.2004.01605.x</pub-id>
<pub-id pub-id-type="pmid">15347324</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>RVPF</given-names></name>, <name><surname>Ramdas</surname><given-names>S</given-names></name>, <name><surname>Nieuwkerk</surname><given-names>P</given-names></name>, <name><surname>Reis</surname><given-names>R</given-names></name>, <name><surname>Lai A Fat</surname><given-names>RFM</given-names></name>, <name><surname>de Vries</surname><given-names>HJC</given-names></name>, <etal>et al</etal>. <article-title>Body location of &#x0201c;New World&#x0201d; cutaneous leishmaniasis lesions and its impact on the quality of life of patients in Suriname</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2020</year>;<volume>14</volume>(<issue>10</issue>):e0008759. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0008759</pub-id>
<pub-id pub-id-type="pmid">33095776</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>EuroQol</surname><given-names>Group</given-names></name>. <article-title>EuroQol--a new facility for the measurement of health-related quality of life</article-title>. <source>Health Policy</source>. <year>1990</year>;<volume>16</volume>(<issue>3</issue>):<fpage>199</fpage>&#x02013;<lpage>208</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0168-8510(90)90421-9</pub-id>
<pub-id pub-id-type="pmid">10109801</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Santos</surname><given-names>M</given-names></name>, <name><surname>Cintra</surname><given-names>MACT</given-names></name>, <name><surname>Monteiro</surname><given-names>AL</given-names></name>, <name><surname>Santos</surname><given-names>B</given-names></name>, <name><surname>Gusm&#x000e3;o-Filho</surname><given-names>F</given-names></name>, <name><surname>Andrade</surname><given-names>MV</given-names></name>, <etal>et al</etal>. <article-title>Brazilian Valuation of EQ-5D-3L Health States: Results from a Saturation Study</article-title>. <source>Med Decis Making</source>. <year>2016</year>;<volume>36</volume>(<issue>2</issue>):<fpage>253</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/0272989X15613521</pub-id>
<pub-id pub-id-type="pmid">26492896</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Viegas Andrade</surname><given-names>M</given-names></name>, <name><surname>Noronha</surname><given-names>K</given-names></name>, <name><surname>Kind</surname><given-names>P</given-names></name>, <name><surname>Maia</surname><given-names>AC</given-names></name>, <name><surname>Miranda de Menezes</surname><given-names>R</given-names></name>, <name><surname>De Barros Reis</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Societal Preferences for EQ-5D Health States from a Brazilian Population Survey</article-title>. <source>Value Health Reg Issues</source>. <year>2013</year>;<volume>2</volume>(<issue>3</issue>):<fpage>405</fpage>&#x02013;<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vhri.2013.01.009</pub-id>
<pub-id pub-id-type="pmid">29702778</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref026"><label>26</label><mixed-citation publication-type="journal"><collab>EuroQol Research Foundation</collab>. EQ-5D-3L User Guide. <year>2018</year>. Available from: <ext-link xlink:href="https://euroqol.org/wp-content/uploads/2019/10/EQ-5D-3L-User-Guide_version-6.0.pdf" ext-link-type="uri">https://euroqol.org/wp-content/uploads/2019/10/EQ-5D-3L-User-Guide_version-6.0.pdf</ext-link></mixed-citation></ref><ref id="pone.0324788.ref027"><label>27</label><mixed-citation publication-type="journal"><collab>ABEP AB de E de P</collab>. Crit&#x000e9;rio Brasil - ABEP. <year>2019</year> [cited 6 Oct 2023]. Available from: <ext-link xlink:href="https://www.abep.org/criterio-brasil" ext-link-type="uri">https://www.abep.org/criterio-brasil</ext-link></mixed-citation></ref><ref id="pone.0324788.ref028"><label>28</label><mixed-citation publication-type="journal"><collab>BRASIL M da Sa&#x000fa;deS-E da Rebrats</collab>. Diretrizes Metodologicas Qualidade de Vida em An&#x000e1;lises Economicas (consulta p&#x000fa;blica). In: Rebrats [Internet]. <day>18</day>
<month>Dec</month>
<year>2023</year> [cited 5 Apr 2024]. Available from: <ext-link xlink:href="https://rebrats.saude.gov.br/images/Documentos/2024/Diretrizes_Metodologicas_Qualidade_de_Vida_em_Analises_Economicas.pdf" ext-link-type="uri">https://rebrats.saude.gov.br/images/Documentos/2024/Diretrizes_Metodologicas_Qualidade_de_Vida_em_Analises_Economicas.pdf</ext-link></mixed-citation></ref><ref id="pone.0324788.ref029"><label>29</label><mixed-citation publication-type="book"><collab>Brasil</collab>. <source>Diretrizes metodol&#x000f3;gicas: Diretriz de Avalia&#x000e7;&#x000e3;o Econ&#x000f4;mica</source>. <edition>2nd edition.</edition>
<publisher-loc>Bras&#x000ed;lia</publisher-loc>; <year>2014</year>. Available from: <ext-link xlink:href="http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_diretriz_avaliacao_economica.pdf" ext-link-type="uri">http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_diretriz_avaliacao_economica.pdf</ext-link></mixed-citation></ref><ref id="pone.0324788.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Vares</surname><given-names>B</given-names></name>, <name><surname>Mohseni</surname><given-names>M</given-names></name>, <name><surname>Heshmatkhah</surname><given-names>A</given-names></name>, <name><surname>Farjzadeh</surname><given-names>S</given-names></name>, <name><surname>Safizadeh</surname><given-names>H</given-names></name>, <name><surname>Shamsi-Meymandi</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Quality of life in patients with cutaneous leishmaniasis</article-title>. <source>Arch Iran Med</source>. <year>2013</year>;<volume>16</volume>(<issue>8</issue>):<fpage>474</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="pmid">23906253</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Balieva</surname><given-names>F</given-names></name>, <name><surname>Kupfer</surname><given-names>J</given-names></name>, <name><surname>Lien</surname><given-names>L</given-names></name>, <name><surname>Gieler</surname><given-names>U</given-names></name>, <name><surname>Finlay</surname><given-names>AY</given-names></name>, <name><surname>Tom&#x000e1;s-Aragon&#x000e9;s</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>The burden of common skin diseases assessed with the EQ5D&#x02122;: a European multicentre study in 13 countries</article-title>. <source>Br J Dermatol</source>. <year>2017</year>;<volume>176</volume>(<issue>5</issue>):<fpage>1170</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/bjd.15280</pub-id>
<pub-id pub-id-type="pmid">28032340</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Nguyen</surname><given-names>SH</given-names></name>, <name><surname>Nguyen</surname><given-names>LH</given-names></name>, <name><surname>Vu</surname><given-names>GT</given-names></name>, <name><surname>Nguyen</surname><given-names>CT</given-names></name>, <name><surname>Le</surname><given-names>THT</given-names></name>, <name><surname>Tran</surname><given-names>BX</given-names></name>, <etal>et al</etal>. <article-title>Health-Related Quality of Life Impairment among Patients with Different Skin Diseases in Vietnam: A Cross-Sectional Study</article-title>. <source>Int J Environ Res Public Health</source>. <year>2019</year>;<volume>16</volume>(<issue>3</issue>):<fpage>305</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijerph16030305</pub-id>
<pub-id pub-id-type="pmid">30678097</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Toniolo-Neto</surname><given-names>J</given-names></name>, <name><surname>Psaradellis</surname><given-names>E</given-names></name>, <name><surname>Karellis</surname><given-names>A</given-names></name>, <name><surname>Rampakakis</surname><given-names>E</given-names></name>, <name><surname>Rockett</surname><given-names>TY</given-names></name>, <name><surname>Sampalis</surname><given-names>JS</given-names></name>, <etal>et al</etal>. <article-title>Measuring herpes zoster disease burden in S&#x000e3;o Paulo, Brazil: a clinico-epidemiological single-center study</article-title>. <source>Clinics (Sao Paulo)</source>. <year>2018</year>;<volume>73</volume>:e243. <comment>doi: </comment><pub-id pub-id-type="doi">10.6061/clinics/2018/e243</pub-id>
<pub-id pub-id-type="pmid">30043824</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>David</surname><given-names>CV</given-names></name>, <name><surname>Craft</surname><given-names>N</given-names></name>. <article-title>Cutaneous and mucocutaneous leishmaniasis</article-title>. <source>Dermatol Ther</source>. <year>2009</year>;<volume>22</volume>(<issue>6</issue>):<fpage>491</fpage>&#x02013;<lpage>502</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1529-8019.2009.01272.x</pub-id>
<pub-id pub-id-type="pmid">19889134</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Goto</surname><given-names>H</given-names></name>, <name><surname>Lauletta Lindoso</surname><given-names>JA</given-names></name>. <article-title>Cutaneous and mucocutaneous leishmaniasis</article-title>. <source>Infect Dis Clin North Am</source>. <year>2012</year>;<volume>26</volume>(<issue>2</issue>):<fpage>293</fpage>&#x02013;<lpage>307</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.idc.2012.03.001</pub-id>
<pub-id pub-id-type="pmid">22632640</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Burza</surname><given-names>S</given-names></name>, <name><surname>Croft</surname><given-names>SL</given-names></name>, <name><surname>Boelaert</surname><given-names>M</given-names></name>. <article-title>Leishmaniasis</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>392</volume>(<issue>10151</issue>):<fpage>951</fpage>&#x02013;<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31204-2</pub-id>
<pub-id pub-id-type="pmid">30126638</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref037"><label>37</label><mixed-citation publication-type="journal"><collab>Dermatology Life Quality Index</collab>. In: Cardiff University [Internet]. <day>14</day>
<month>Mar</month>
<year>2019</year> [cited 11 Jul 2024]. Available: <ext-link xlink:href="https://www.cardiff.ac.uk/medicine/resources/quality-of-life-questionnaires/dermatology-life-quality-index" ext-link-type="uri">https://www.cardiff.ac.uk/medicine/resources/quality-of-life-questionnaires/dermatology-life-quality-index</ext-link></mixed-citation></ref><ref id="pone.0324788.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Zimmermann</surname><given-names>IR</given-names></name>, <name><surname>Silva</surname><given-names>MT</given-names></name>, <name><surname>Galvao</surname><given-names>TF</given-names></name>, <name><surname>Pereira</surname><given-names>MG</given-names></name>. <article-title>Health-related quality of life and self-reported long-term conditions: a population-based survey</article-title>. <source>Braz J Psychiatry</source>. <year>2017</year>;<volume>39</volume>(<issue>1</issue>):<fpage>62</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1590/1516-4446-2015-1853</pub-id>
<pub-id pub-id-type="pmid">27533021</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Fujikawa</surname><given-names>A</given-names></name>, <name><surname>Suzue</surname><given-names>T</given-names></name>, <name><surname>Jitsunari</surname><given-names>F</given-names></name>, <name><surname>Hirao</surname><given-names>T</given-names></name>. <article-title>Evaluation of health-related quality of life using EQ-5D in Takamatsu, Japan</article-title>. <source>Environ Health Prev Med</source>. <year>2011</year>;<volume>16</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s12199-010-0162-1</pub-id>
<pub-id pub-id-type="pmid">21432214</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Moussavi</surname><given-names>S</given-names></name>, <name><surname>Chatterji</surname><given-names>S</given-names></name>, <name><surname>Verdes</surname><given-names>E</given-names></name>, <name><surname>Tandon</surname><given-names>A</given-names></name>, <name><surname>Patel</surname><given-names>V</given-names></name>, <name><surname>Ustun</surname><given-names>B</given-names></name>. <article-title>Depression, chronic diseases, and decrements in health: results from the World Health Surveys</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>(<issue>9590</issue>):<fpage>851</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61415-9</pub-id>
<pub-id pub-id-type="pmid">17826170</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Santos</surname><given-names>M</given-names></name>, <name><surname>Monteiro</surname><given-names>AL</given-names></name>, <name><surname>Santos</surname><given-names>B</given-names></name>. <article-title>EQ-5D Brazilian population norms</article-title>. <source>Health Qual Life Outcomes</source>. <year>2021</year>;<volume>19</volume>(<issue>1</issue>):<fpage>162</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12955-021-01671-6</pub-id>
<pub-id pub-id-type="pmid">34112207</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>EL-Y</given-names></name>, <name><surname>Cheung</surname><given-names>AW-L</given-names></name>, <name><surname>Wong</surname><given-names>AY-K</given-names></name>, <name><surname>Xu</surname><given-names>RH</given-names></name>, <name><surname>Ramos-Go&#x000f1;i</surname><given-names>JM</given-names></name>, <name><surname>Rivero-Arias</surname><given-names>O</given-names></name>. <article-title>Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L</article-title>. <source>Value Health</source>. <year>2019</year>;<volume>22</volume>(<issue>8</issue>):<fpage>916</fpage>&#x02013;<lpage>24</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jval.2019.02.014</pub-id>
<pub-id pub-id-type="pmid">31426933</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Mina</surname><given-names>S</given-names></name>, <name><surname>Jabeen</surname><given-names>M</given-names></name>, <name><surname>Singh</surname><given-names>S</given-names></name>, <name><surname>Verma</surname><given-names>R</given-names></name>. <article-title>Gender differences in depression and anxiety among atopic dermatitis patients</article-title>. <source>Indian J Dermatol</source>. <year>2015</year>;<volume>60</volume>(<issue>2</issue>):<fpage>211</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4103/0019-5154.152564</pub-id>
<pub-id pub-id-type="pmid">25814727</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Sampogna</surname><given-names>F</given-names></name>, <name><surname>Chren</surname><given-names>MM</given-names></name>, <name><surname>Melchi</surname><given-names>CF</given-names></name>, <name><surname>Pasquini</surname><given-names>P</given-names></name>, <name><surname>Tabolli</surname><given-names>S</given-names></name>, <name><surname>Abeni</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis</article-title>. <source>Br J Dermatol</source>. <year>2006</year>;<volume>154</volume>(<issue>2</issue>):<fpage>325</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1365-2133.2005.06909.x</pub-id>
<pub-id pub-id-type="pmid">16433804</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>DE</given-names></name>, <name><surname>Thompson</surname><given-names>JK</given-names></name>, <name><surname>Raczynski</surname><given-names>JM</given-names></name>, <name><surname>Hilner</surname><given-names>JE</given-names></name>. <article-title>Body image among men and women in a biracial cohort: The CARDIA study</article-title>. <source>Int J Eat Disord</source>. <year>1999</year>;<volume>25</volume>(<issue>1</issue>):<fpage>71</fpage>&#x02013;<lpage>82</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/(sici)1098-108x(199901)25:1&#x0003c;71::aid-eat9&#x0003e;3.0.co;2-3</pub-id><pub-id pub-id-type="pmid">9924655</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Blome</surname><given-names>C</given-names></name>, <name><surname>Augustin</surname><given-names>M</given-names></name>. <article-title>Measuring change in quality of life: bias in prospective and retrospective evaluation</article-title>. <source>Value Health</source>. <year>2015</year>;<volume>18</volume>(<issue>1</issue>):<fpage>110</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jval.2014.10.007</pub-id>
<pub-id pub-id-type="pmid">25595241</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref047"><label>47</label><mixed-citation publication-type="journal"><collab>Catalogue of Bias Collaboration, Spencer E, Brassey J, Mahtani K</collab>. Recall bias. In: Catalog of Bias [Internet]. <day>20</day>
<month>Jul</month>
<year>2017</year> [cited 7 Aug 2024]. Available from: <ext-link xlink:href="https://catalogofbias.org/biases/recall-bias/" ext-link-type="uri">https://catalogofbias.org/biases/recall-bias/</ext-link>.</mixed-citation></ref><ref id="pone.0324788.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Esperidi&#x000e3;o</surname><given-names>M</given-names></name>, <name><surname>Trad</surname><given-names>LAB</given-names></name>. <article-title>Avalia&#x000e7;&#x000e3;o de satisfa&#x000e7;&#x000e3;o de usu&#x000e1;rios</article-title>. <source>Ci&#x000ea;nc sa&#x000fa;de coletiva</source>. <year>2005</year>;<volume>10</volume>(suppl):<fpage>303</fpage>&#x02013;<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1590/s1413-81232005000500031</pub-id></mixed-citation></ref><ref id="pone.0324788.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Owens</surname><given-names>DJ</given-names></name>, <name><surname>Batchelor</surname><given-names>C</given-names></name>. <article-title>Patient satisfaction and the elderly</article-title>. <source>Soc Sci Med</source>. <year>1996</year>;<volume>42</volume>(<issue>11</issue>):<fpage>1483</fpage>&#x02013;<lpage>91</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0277-9536(95)00234-0</pub-id>
<pub-id pub-id-type="pmid">8771631</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Bernhart</surname><given-names>MH</given-names></name>, <name><surname>Wiadnyana</surname><given-names>IG</given-names></name>, <name><surname>Wihardjo</surname><given-names>H</given-names></name>, <name><surname>Pohan</surname><given-names>I</given-names></name>. <article-title>Patient satisfaction in developing countries</article-title>. <source>Soc Sci Med</source>. <year>1999</year>;<volume>48</volume>(<issue>8</issue>):<fpage>989</fpage>&#x02013;<lpage>96</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0277-9536(98)00376-1</pub-id>
<pub-id pub-id-type="pmid">10390039</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Junejo</surname><given-names>MH</given-names></name>, <name><surname>Wolfe</surname><given-names>I</given-names></name>, <name><surname>Patel</surname><given-names>J</given-names></name>, <name><surname>Duus</surname><given-names>E</given-names></name>, <name><surname>Oyebanji</surname><given-names>O</given-names></name>, <name><surname>Walker</surname><given-names>SL</given-names></name>. <article-title>Use of the Dermatology Life Quality Index suite of patient-reported outcome measures in skin-related neglected tropical diseases</article-title>. <source>Br J Dermatol</source>. <year>2023</year>;<volume>189</volume>(<issue>4</issue>):<fpage>490</fpage>&#x02013;<lpage>2</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bjd/ljad217</pub-id>
<pub-id pub-id-type="pmid">37399250</pub-id>
</mixed-citation></ref><ref id="pone.0324788.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Conteh</surname><given-names>L</given-names></name>, <name><surname>Engels</surname><given-names>T</given-names></name>, <name><surname>Molyneux</surname><given-names>DH</given-names></name>. <article-title>Socioeconomic aspects of neglected tropical diseases</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>(<issue>9710</issue>):<fpage>239</fpage>&#x02013;<lpage>47</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61422-7</pub-id>
<pub-id pub-id-type="pmid">20109925</pub-id>
</mixed-citation></ref></ref-list></back><sub-article article-type="author-comment" id="pone.0324788.r001" specific-use="rebutted-decision-letter-unavailable"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0324788.r001</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">30 Dec 2024</named-content>
</p></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0324788.r002" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0324788.r002</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Belo</surname><given-names>Vin&#x000ed;cius Silva</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Vin&#x000ed;cius Silva Belo</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Vin&#x000ed;cius Silva Belo</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0324788" id="rel-obj002" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">24 Feb 2025</named-content>
</p><p>PONE-D-24-57829Health-related quality of life in patients with cutaneous leishmaniasis in Brazil using EQ-5DPLOS ONE</p><p>Dear Dr. Silva,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please consider the points raised by the reviewers. I emphasize the need for additional statistical analyses to adequately address the concerns raised by Reviewer #1.</p><p>Please submit your revised manuscript by Apr 10 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#x000a0;<email>plosone@plos.org</email> . When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link> . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link> .</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Vin&#x000ed;cius Silva Belo</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal requirements:</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1.&#x000a0; Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p><p><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> &#x000a0; and</p><p>
<ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
</p><p>2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). Since your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.</p><p>3. Thank you for stating the following financial disclosure:</p><p>&#x0201c;Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico - CNPq (GC grant:</p><p>302069/2022-4)&#x0201d;</p><p>Please state what role the funders took in the study.&#x000a0; If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."</p><p>If this statement is not correct you must amend it as needed.</p><p>Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.</p><p>4. In the online submission form, you indicated that your data is available only on request from a third party. Please note that your Data Availability Statement is currently missing the name of the third party contact or institution / contact details for the third party, such as an email address or a link to where data requests can be made. Please update your statement with the missing information.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Author</bold>
</p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#x000a0;Partly</p><p>Reviewer #2:&#x000a0;Partly</p><p>Reviewer #3: Yes</p><p>**********</p><p>2. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#x000a0;No</p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #1: Yes</p><p>**********</p><p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.</p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3: Yes</p><p>**********</p><p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3: Yes</p><p>**********</p><p>5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1:&#x000a0;Evaluation of the article entitled: Health-related quality of life in patients with cutaneous leishmaniasis in Brazil using EQ-5D</p><p>Overall impression</p><p>The topic/problem addressed is highly relevant and needs to be shared. However, the article presents methodological weaknesses that limit its publication, including the following: the study design is described as cross-sectional; however, the methodology presents the same comparison variables within the same population at different moments (before the CL diagnosis and after the onset of the first symptoms), which would characterize it as longitudinal.</p><p>Another highly relevant aspect is the uniform use of questionnaires to assess "quality of life," which involve variables such as, mobility and self-care, among people of widely varying age groups. These variables (mobility and self-care) are categorized differently across age groups. For example, I do not think it is appropriate to compare the mobility of a 12-year-old person with that of someone over 74 years old.</p><p>Moreover, the exclusion criteria were not clearly defined. For instance, wouldn't a person with a prior diagnosis of depression constitute a confounding bias? Furthermore, the results do not clearly indicate whether the "decline" in quality of life was independently associated with the onset of CL symptoms or if it could have been influenced by other health conditions, like as long-standing diabetes mellitus.</p><p>Analysis by items</p><p>Abstract:</p><p>&#x02714;Line 27: Review the phrase: "in patients with CL in patients." There is a repetition of terms ("in patients").</p><p>&#x02714;Objective: I suggest removing "in patients attending a Brazilian reference center, using the EQ-5D-3L/VAS questionnaire to generate utility measures for this disease," as this information is better suited for the "Methods" section.</p><p>Methods:</p><p>&#x02714; the study design is described as cross-sectional; however, the methodology presents the same comparison variables within the same population at different moments (before the LC diagnosis and after the onset of the first symptoms), which would characterize it as longitudinal.</p><p>Results:</p><p>&#x02714;The sentence "The mean utility score before the onset of CL symptoms was 0.858. A comparison of the responses related to health status before and after the illness revealed significant losses (p&#x0003c;0.05) in all dimensions of the EQ-5D, especially those related to pain, malaise, and usual activities, which were reduced to 50% and 27%, respectively" seems paradoxical. The way it is written suggests a reduction in pain, malaise, and activities. I suggest rewording this sentence.</p><p>Article text</p><p>&#x02714;Introduction</p><p>I suggest explicitly stating the objective in the introduction.</p><p>&#x02714;Methods:</p><p>&#x0fffd;<!-- &#x0f0d8; --> Study design: Considering that the same individuals were evaluated with the same variables at different time points (before the onset of symptoms and during the active phase of CL), I suggest revising the study design to be described as longitudinal.</p><p>&#x0fffd;<!-- &#x0f0d8; --> I suggest clarifying the variable used to assess health status before and during the active phase of CL. For example: How was the timeframe determined to define the period before symptom onset? (One week before? One month before? One year before?). Regarding the active disease phase, it is crucial to specify that it was 30 days after symptom onset.</p><p>&#x0fffd;<!-- &#x0f0d8; --> The age range of participants varied from adolescence (12 years and older) to elderly individuals (over 74 years old). It would be essential to explain the rationale for selecting this age range because quality of life is sensitive to age. For example, mobility or self-care (as evaluated in the questionnaire) before symptom onset and during the active disease phase may not be comparable between a 12-year-old individual and someone over 74.</p><p>&#x0fffd;<!-- &#x0f0d8; --> It would be essential to clarify whether an analysis was conducted to assess quality of life in association with socioeconomic, sociodemographic, and clinical variables, such as age and comorbidities.</p><p>&#x0fffd;<!-- &#x0f0d8; --> I suggest further clarifying the inclusion criteria. For example, were individuals with a prior diagnosis of depression and/or anxiety included in the study?</p><p>&#x02714;Results:</p><p>&#x0fffd;<!-- &#x0f0d8; --> I believe it would be more objective to concisely describe the convenience sample relative to the total eligible population.</p><p>&#x0fffd;<!-- &#x0f0d8; --> The statement "The VAS results support the magnitude of this loss, with the average score reported by patients before CL being 87 and decreasing to 70 during active CL, representing a loss of 19.5%" needs a clearer statistical description to demonstrate that this score reduction on the VAS was significant and independently associated with the CL diagnosis. (It is stated that more than 50% of participants had comorbidities such as diabetes and hypertension, some of whom were untreated, which could be a factor affecting vision.)</p><p>&#x0fffd;<!-- &#x0f0d8; --> I suggest avoiding repetition of information from the table in the text, as it becomes redundant. Instead, keep only complementary details in the text.</p><p>&#x0fffd;<!-- &#x0f0d8; --> I recommend completing the table titles so that they can be interpreted and understood independently of the text. For example, missing details include location and study period.</p><p>&#x0fffd;<!-- &#x0f0d8; --> The age groups in the results table were categorized in a non-standard manner. I suggest explaining this categorization in the Methods section or providing a reference to justify it. I reinforce that the broad age range may impact quality of life differently among individuals with CL.</p><p>&#x0fffd;<!-- &#x0f0d8; --> The figures are not clear; I suggest improving their resolution for better readability.</p><p>Reviewer #2:&#x000a0;Its interesting manuscript about the "Health-related quality of life in patients with cutaneous leishmaniasis in Brazil using EQ-5D".</p><p>The manuscript presents a well-structured study on the impact of cutaneous leishmaniasis (CL) on health-related quality of life (HRQoL) using the EQ-5D-3L instrument in a Brazilian cohort. The study addresses an important gap in the literature by quantitatively assessing the disease burden using standardized measures. The methodology is sound, and the statistical analyses are appropriate. However, there are some areas that require improvement in structure, clarity, and interpretation of results.</p><p>1. Title and Abstract</p><p>Title: The title is clear and informative but could be slightly refined for conciseness. Suggested revision:</p><p>"Health-Related Quality of Life in Brazilian Patients with Cutaneous Leishmaniasis Using EQ-5D-3L".</p><p>Abstract: The abstract is well-structured but contains minor grammatical errors and awkward phrasing.</p><p>The sentence "The aim of the present study was quantitatively assess the health-related quality of life..." should be rewritten as:</p><p>"The aim of this study was to quantitatively assess the health-related quality of life..."</p><p>The conclusion could be more impactful by emphasizing the broader implications for public health and policy.</p><p>2. Introduction</p><p>The introduction provides a strong rationale for the study, outlining the burden of CL and the importance of HRQoL assessment.</p><p>The references are relevant, but the discussion of previous studies could be slightly condensed to improve readability.</p><p>The sentence "However, no studies were found that quantitatively defined the health utility of CL." might be misleading because studies have assessed QoL in CL patients using different instruments. Instead, it should specify that no utility-based HRQoL assessments had been conducted.</p><p>3. Methods</p><p>The study design and statistical approach are well-described.</p><p>The retrospective assessment of pre-disease HRQoL introduces recall bias, which is acknowledged, but additional justification on why this approach was necessary could strengthen the discussion.</p><p>The use of EQ-5D-3L is appropriate, but a brief mention of why this tool was preferred over disease-specific QoL instruments (e.g., Dermatology Life Quality Index) would be beneficial.</p><p>The sample size justification is missing&#x02014;was a power calculation conducted?</p><p>Recommendation: Moderate revision to clarify study design choices and add justification for the sample size.</p><p>4. Results</p><p>The results are clearly presented with appropriate statistical analyses.</p><p>Figures and tables are well-organized but should be cross-referenced more explicitly in the text.</p><p>The finding that pain/discomfort and usual activities were the most affected dimensions is expected but could be better contextualized with references to similar conditions (e.g., post-herpetic neuralgia, chronic skin conditions).</p><p>There is no discussion of potential sex-based differences despite reporting a significant difference in baseline HRQoL scores between men and women.</p><p>Recommendation: Moderate revision to improve result interpretation and discuss observed differences more thoroughly.</p><p>5. Discussion</p><p>The discussion effectively summarizes key findings and places them in context.</p><p>The authors compare their utility scores with those from studies on other diseases (e.g., HIV, herpes zoster), which is useful but should be expanded to explain why these comparisons are relevant.</p><p>Some speculative statements require more evidence, e.g., "These findings underscore the severity of the impact of CL on QoL, which is comparable to that of other chronic and debilitating diseases."&#x02014;This should be supported by additional references or phrased more cautiously.</p><p>The limitations section is comprehensive, but it does not address potential selection bias&#x02014;since patients were recruited from a referral center, they may represent more severe cases of CL.</p><p>Recommendation: Major revision to strengthen discussion points and refine conclusions.</p><p>6. Conclusion</p><p>The conclusion aligns with the study&#x02019;s findings but could be more impactful by emphasizing the implications for clinical care and policymaking.</p><p>The sentence "To maximize the value of these studies, it is crucial to continue enhancing assessment instruments..." is vague&#x02014;what specific improvements are suggested?</p><p>Recommendation: Minor revision for a stronger takeaway message.</p><p>Final Decision</p><p>&#x02611; Major Revision Required</p><p>Justification: While the study is methodologically sound and addresses an important research gap, it requires significant refinements in the discussion, result interpretation, and methodological justification. The authors should focus on improving clarity, addressing potential biases, and strengthening their argumentation.</p><p>Once the revisions are completed, the manuscript is likely to be suitable for publication.</p><p>Reviewer #3:&#x000a0;The manuscript provides valuable insights into the health-related quality of life (HRQoL) in cutaneous leishmaniasis (CL) patients using the EQ-5D-3L/VAS questionnaire. The study is well-designed, and the data appropriately support the conclusions. However, some minor revisions are recommended:</p><p><list list-type="order"><list-item><p><bold>Clarity &#x00026; Readability:</bold> &#x000a0;Some sentences need&#x000a0;rewriting . For example, &#x0201c;The aim of the present study was quantitatively assess&#x02026;&#x0201d; should be revised to &#x0201c;The aim of this study was to quantitatively assess&#x02026;&#x0201d;. Consider reviewing sentence structures for clarity.</p></list-item><list-item><p><bold>Terminology:</bold> &#x000a0;Replace &#x0201c;transversal study&#x0201d; with &#x0201c;cross-sectional study&#x0201d; for better clarity, as the latter is the standard term in English-language research.</p></list-item></list>
</p><p>Overall, the manuscript is of high quality and makes a valuable contribution to the understanding of CL&#x02019;s impact on HRQoL. With minor revisions for clarity and precision, it will be suitable for publication.&#x000a0;&#x000a0;</p><p>I have no competing interest</p><p>No body assisted me in preparing this review</p><p>**********</p><p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link> ). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link> .</p><p>Reviewer #1:&#x000a0;No</p><p>Reviewer #2:&#x000a0;<bold>Yes:&#x000a0;</bold> Mehdi Azami</p><p>Reviewer #3:&#x000a0;Shimelis Nigusse Doni</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#x000a0;<ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link> . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#x000a0;<email>figures@plos.org</email> . Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article article-type="author-comment" id="pone.0324788.r003"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0324788.r003</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0324788" id="rel-obj003" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">3 Apr 2025</named-content>
</p><p>Dear reviewers</p><p>We would like to thank the reviewers for their careful review of the manuscript "Health-related quality of life in patients with cutaneous leishmaniasis in Brazil using EQ-5D" (PONE-D-24-57829), now with the changed title &#x0201c;Health-related quality of life in Brazilian patients with cutaneous leishmaniasis using EQ-5D&#x0201d;. This opportunity to improve our work makes it even more robust and useful to the scientific community - our sole goal.</p><p>We did our best to improve the text accordingly. The modifications implemented in this revised version are summarized below together with specific answers to the questions placed by the reviewers.</p><p>We reinforced that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p><p>We hope the reviewers find our responses to their comments satisfactory. Please let us know if any further improvements to the manuscript are needed.</p><p>Sincerely yours,</p><p>Sarah Silva</p><supplementary-material id="pone.0324788.s005" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers_26.3.25.docx</named-content></p></caption><media xlink:href="pone.0324788.s005.docx"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0324788.r004" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0324788.r004</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Belo</surname><given-names>Vin&#x000ed;cius Silva</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Vin&#x000ed;cius Silva Belo</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Vin&#x000ed;cius Silva Belo</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0324788" id="rel-obj004" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">2 May 2025</named-content>
</p><p>Health-related quality of life in Brazilian patients with cutaneous leishmaniasis using EQ-5D</p><p>PONE-D-24-57829R1</p><p>Dear Dr. Silva,</p><p>We&#x02019;re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#x02019;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#x02019;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#x000ae;</ext-link> &#x000a0;and clicking the &#x02018;Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#x02019;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>Kind regards,</p><p>Vin&#x000ed;cius Silva Belo</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#x0201c;Comments to the Author&#x0201d; section, enter your conflict of interest statement in the &#x0201c;Confidential to Editor&#x0201d; section, and submit your "Accept" recommendation.</p><p>Reviewer #1:&#x000a0;All comments have been addressed</p><p>Reviewer #2:&#x000a0;All comments have been addressed</p><p>**********</p><p>2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p>3. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.</p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p>6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1:&#x000a0;I agree with approving the article after the authors have revised it. They were careful and made the requested changes, from format to meet the plos one guidelines to weaknesses that compromised the excellence of the research, including changing the study design.</p><p>Reviewer #2:&#x000a0;Dear authors,</p><p>The article has been revised and corrected as requested. At this stage, I consider it acceptable for publication and will make a recommendation to the editor as to its suitability.</p><p>**********</p><p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link> ). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link> .</p><p>Reviewer #1:&#x000a0;No</p><p>Reviewer #2:&#x000a0;<bold>Yes:&#x000a0;</bold> Mehdi Azami</p><p>**********</p></body></sub-article><sub-article article-type="editor-report" id="pone.0324788.r005" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0324788.r005</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Belo</surname><given-names>Vin&#x000ed;cius Silva</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Vin&#x000ed;cius Silva Belo</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Vin&#x000ed;cius Silva Belo</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0324788" id="rel-obj005" related-article-type="reviewed-article"/></front-stub><body><p>PONE-D-24-57829R1</p><p>PLOS ONE</p><p>Dear Dr. Silva,</p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>You will receive further&#x000a0;instructions from the production team, including instructions on how to review your proof when it&#x000a0;is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.</p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>If we can help with anything else, please email us at customercare@plos.org.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access.</p><p>Kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Vin&#x000ed;cius Silva Belo</p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article>